<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252339</url>
  </required_header>
  <id_info>
    <org_study_id>GO43242</org_study_id>
    <secondary_id>REFMAL 678</secondary_id>
    <nct_id>NCT04252339</nct_id>
  </id_info>
  <brief_title>RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in&#xD;
      subjects with advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and&#xD;
      preliminary anti-tumor activity of RLY-1971. Approximately 70 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Escalation Phase - 18 month Enrollment</time_frame>
    <description>MTD is defined as a dose level immediately below that at which ≥2 of 6 subjects experience a DLT during the first cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Escalation Phase - 18 month Enrollment</time_frame>
    <description>RP2D may be the same dose level or lower than the determined MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration levels of RLY-1971</measure>
    <time_frame>At the beginning of Cycle 1 &amp; Cycle 2 (Each Cycle is 21 days)</time_frame>
    <description>Blood samples may be taken at pre-dose, 0.5, 1, 2, 4, 6, and 8hrs on Cycle 1 Day 1 and 15, 24 hrs post dose on Cycle 1 Day 2, and pre-dose on Cycle 2 Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>Evaluation by RECIST 1.1; ORR is defined as the proportion of subjects in the response evaluable population who achieve the best overall response (BOR) of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>DCR is defined as the percentage of response evaluable subjects who achieve a BOR of CR, PR or SD for at least 3 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in phospho-ERK levels</measure>
    <time_frame>At the beginning of Cycle 1 Day 1 post and pre</time_frame>
    <description>Blood will be collected at pre-dose at baseline on Cycle 1, Day 1 (C1D1) and at 3 time points (pre-dose, 2 hours post-dose, and 4 hours post-dose) on Cycle 1, Day 15 (C1D15) to assess the extent of target engagement</description>
  </other_outcome>
  <other_outcome>
    <measure>Tumor mutations by sequencing circulating tumor DNA (ctDNA)</measure>
    <time_frame>At the beginning of Cycle 1 Day 1</time_frame>
    <description>Blood will be collected at screening and at End of Treatment on all patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to RLY-1971, to disease progression or death due to any cause, whichever occurs first</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Through study completion (an average of one year)</time_frame>
    <description>PFS is defined as the time from the start of study treatment to the first documented disease progression per RECIST v1.1, or death due to any cause, whichever occurs first</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Solid Tumor, Unspecified, Adult</condition>
  <arm_group>
    <arm_group_label>RLY-1971 - Dose Escalation/Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified&#xD;
Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLY-1971</intervention_name>
    <description>RLY-1971 is an oral inhibitor of SHP2.</description>
    <arm_group_label>RLY-1971 - Dose Escalation/Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is willing and able to provide written informed consent for the study prior to&#xD;
             the performance of any study-specific procedures&#xD;
&#xD;
          2. Subject is a male or female subject ≥18 years of age at the time of consent&#xD;
&#xD;
          3. Subject must have an ECOG PS ≤ 1&#xD;
&#xD;
          4. Subject must have histologically or cytologically confirmed advanced or metastatic&#xD;
             solid tumor&#xD;
&#xD;
          5. Subjects who are refractory to FDA-approved, standard therapy or for which standard or&#xD;
             curative therapy does not exist or is not considered sufficient or appropriate by the&#xD;
             patient or Investigator&#xD;
&#xD;
          6. Subject must have radiographically measurable or evaluable disease&#xD;
&#xD;
          7. Subject must have recovered from the reversible effects of prior anti-neoplastic&#xD;
             therapy, except for alopecia and ≤ grade 2 neuropathy.&#xD;
&#xD;
          8. Subject has adequate end organ function&#xD;
&#xD;
          9. Subject is willing to comply with all protocol-required visits, assessments, and&#xD;
             procedures&#xD;
&#xD;
         10. Male and female subjects of child-bearing potential are willing to use medically&#xD;
             acceptable methods of birth control from the screening visit through 30 days after the&#xD;
             last dose of study medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with documented history of tumor mutations that may not be amenable to&#xD;
             treatment with RLY-1971, including:&#xD;
&#xD;
               1. KRAS mutations: G12D, G12V, G13X, and Q61X&#xD;
&#xD;
               2. BRAF V600E mutation&#xD;
&#xD;
               3. MEK mutations&#xD;
&#xD;
          2. Subjects with prior antineoplastic therapy within 3 weeks of Study Day 1, or 5&#xD;
             half-lives, whichever is shorter&#xD;
&#xD;
          3. Subjects with prior palliative radiotherapy within 1 week of Study Day 1&#xD;
&#xD;
          4. Subjects who have had major surgery or trauma, or incomplete recovery from surgery or&#xD;
             trauma, within 4 weeks of Study Day 1&#xD;
&#xD;
          5. Subjects with known central nervous system (CNS) metastases or primary CNS tumor that&#xD;
             is associated with progressive neurologic symptoms or requires increasing doses of&#xD;
             corticosteroids to control the CNS disease. If patient requires corticosteroids for&#xD;
             management of CNS disease, the dose must have been stable for the 2 weeks preceding&#xD;
             C1D1, or subject has new lesions appearing on follow up brain MRI that require&#xD;
             CNS-directed intervention.&#xD;
&#xD;
          6. Subjects with a history or evidence of ophthalmic disease&#xD;
&#xD;
          7. Subjects with a history or evidence of significant cardiac dysfunction&#xD;
&#xD;
          8. Subjects with a history or evidence of significant gastrointestinal disease&#xD;
&#xD;
          9. Subjects with other serious concurrent medical conditions&#xD;
&#xD;
         10. Subject is pregnant, as documented by a serum beta human chorionic gonadotropin&#xD;
             (β-hCG) pregnancy test consistent with pregnancy obtained within 7 days before the&#xD;
             first dose of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO43242 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S.)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shekeab Jauhari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judy Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey Shapiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Bullock, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Advanced or Metastatic Solid Tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>First in Human (FIH)</keyword>
  <keyword>SHP2 inhibition</keyword>
  <keyword>PTPN11</keyword>
  <keyword>Bypass Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

